cefprozil

Código ATC

J01DC10

Clase terapéutica

Antibacterianos de uso sistémico · Cefalosporina de segunda generación

Formas

Comprimidos orales de cefprozil de 250 o 500 mg

Marcas comerciales

Cefprozil (US)

Confianza global

alta

Fuentes regulatorias consultadas

Indicaciones aprobadas

Infecciones leves-moderadas sensibles de vías respiratorias superiores e inferiores y piel.

Contraindicaciones

Absolutas

Hipersensibilidad a cefprozil o cefalosporinas.

Advertencias clínicas

Advertencia mayor · Puede causar hipersensibilidad grave o anafilaxia. Antes de administrarlo, revisa antecedentes de reacción inmediata a betalactámicos y suspende si aparece una reacción alérgica. — FDA, set_id 14527f4a-ce99-449d-a5a5-9edd7fb28dee
Advertencia mayor · Puede producir diarrea asociada a Clostridioides difficile durante o después del tratamiento; evalúa diarrea importante y evita antiperistálticos si se sospecha colitis. — FDA, set_id 14527f4a-ce99-449d-a5a5-9edd7fb28dee

Interacciones medicamentosas

ModeradaProbenecid
Mecanismo: Reduce la secreción tubular renal y puede aumentar y prolongar la exposición al antibiótico.
Recomendación: Evita la combinación salvo indicación deliberada y vigila toxicidad.
FDA, set_id 14527f4a-ce99-449d-a5a5-9edd7fb28dee
SeveraAminoglucósidos y otros nefrotóxicos
Mecanismo: La combinación puede aumentar la nefrotoxicidad.
Recomendación: Evita la combinación cuando sea posible y controla la función renal.
FDA, set_id 14527f4a-ce99-449d-a5a5-9edd7fb28dee

Eventos adversos

Comunes (≥1%)

Náuseas, diarrea y erupción cutánea

Raros pero graves

Anafilaxia, colitis por C. difficile y citopenias graves

Embarazo y lactancia

Usar durante el embarazo solo cuando esté claramente indicado. Pasa a la leche en pequeñas cantidades; vigila diarrea, candidiasis o sensibilización en el lactante y valora la continuidad según el producto.

Bibliografía reciente (PubMed)

Pharmacokinetic and Bioequivalence Evaluation of Two Cefprozil Dispersible Tablets in Healthy Chinese Volunteers.
Xu L, et al. · Clin Pharmacol Drug Dev · 2023 · Relevancia 1/5
This study aimed to assess the bioequivalence of 2 cefprozil dispersible tablet formulations (250 mg) in healthy Chinese volunteers under fasting and fed conditions and to determine the pharmacokinetics of cefprozil. A randomized, single-dose, open-label, 2-formulation, 2-period study was conducted. The elimination period for this study was 7 days. Forty-eight healthy volunteers received 250-mg cefprozil dispersible tablets in each study period under both test and reference conditions. The test and the reference cefprozil were bioequivalent in healthy Chinese volunteers, and there was no significant food effect in individuals receiving either formulation. No serious adverse event was recorded, and no volunteers withdrew from the study.
Efficacy and safety of 24 antibiotics for group A streptococcal pharyngitis: a network meta-analysis of 64 randomized controlled trials.
Sun X, et al. · Front Public Health · 2026 · Relevancia 1/5
Penicillin remains the first-line therapy for group A streptococcal (GAS) pharyngitis. However, broad-spectrum antibiotics continue to be widely prescribed in clinical practice. This study aimed to evaluate the relative efficacy and safety profiles of antibiotics for GAS pharyngitis. Literature published through March 2026 was searched. Efficacy outcomes included early and late bacterial eradication, clinical response, and bacteriological recurrence, whereas safety was assessed according to adverse events. Per-protocol data were extracted, and a Bayesian network meta-analysis was performed to estimate pooled odds ratios (ORs) with 95% confidence intervals (CIs). We identified 64 RCTs (23,287 participants). For early bacterial eradication, cefdinir (OR: 3.09; 95% CI: 1.60-6.01) and cefpodoxime proxetil (OR: 2.58; 95% CI: 1.07-6.17) demonstrated greater efficacy compared with penicillin V, whereas azithromycin showed inferior eradication rates than penicillin V (OR: 0.53; 95% CI: 0.32-0.90). For late bacterial eradication, cefprozil demonstrated greater efficacy compared with penicillin V (OR: 3.12; 95% CI: 1.03-11.25), whereas azithromycin exhibited suboptimal performance (OR: 0.38; 95% CI: 0.25-0.62). For early clinical response, cefdinir (OR: 2.01; 95% CI: 1.28-3.25) and cefuroxime axetil (OR: 2.14; 95% CI: 1.19-3.60) demonstrated significantly greater efficacy compared with penicillin V. For late clinical response, spiramycin showed superior efficacy to penicillin V (OR: 0.17; 95% CI: 0.02-0.94), although evidence was limited to a single small trial. Azithromycin was associated with reduced efficacy, higher late recurrence rates, and increased adverse events. Standard penicillins should remain the preferred first-line therapy for GAS pharyngitis to support antimicrobial stewardship. Cefdinir represents an effective alternative. Conversely, azithromycin should be avoided due to inferior efficacy and increased adverse risks. http://www.crd.york.ac.uk/prospero, ident